Heart Septal Defects, Atrial

TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc’s Palmitoylethanolamide (“PEA”). This innovative combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment. Eating disorders are serious mental health conditions that negatively impact an individual’s health, emotions, and ability to perform daily functions. Eating disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders. According to recent studies, up to 70 million people globally are affected by eating disorders, with significant increases observed among children and adolescents. Global eating disorder prevalence increased from 3.4% to 7.8% between 2000 and 2018. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on Amazon Marketplace. About Clearmind Medicine Inc. (“Clearmind”) Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Common shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.” For further information visit: https://www.clearmindmedicine.com Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential of its proprietary treatment to treat anorexia, bulimia and other eating disorders. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

TUESDAY, April 8, 2025 -- A non-intoxicating extract of cannabis appears to help children and teenagers with autism, a new study says. Cannabidiol (CBD) enhanced social responsiveness, reduced disruptive behavior and alleviated anxiety among kids with autism, researchers reported today at the European Congress of Psychiatry in Madrid. “The global population prevalence of autism spectrum disorder diagnosis amongst children and adolescents is growing, but many treatment pathways are not effective,” lead researcher Dr. Lara Branco , a psychiatrist at the University of São Paulo in Brazil, said in a news release. “It is promising to see the effect of CBD cannabis extract on the study participants,” she continued. For the study, researchers pooled data from three previous clinical trials looking into the use of CBD extracts to treat 276 children with autism. Their average age was 10-1/2 years old. Cannabidiol is the second most prevalent active ingredient in marijuana, according to Harvard Medical School. Unlike THC, CBD does not cause intoxication, but researchers believe it can produce health benefits by acting upon cannabinoid receptors throughout the brain and body. The new results show that CBD does indeed appear to have a calming effect on children with autism, helping them become more responsive to others and less anxious. CBD also appeared to improve kids’ sleep quality, although those results were not statistically significant. “ASD can be extremely frustrating for all involved; parents of children and adolescents with the disorder, the treating clinicians, and of course the children and adolescents themselves,” European Psychiatric Association President Dr. Geert Dom said in a news release. “A large part of this frustration is down to finding a viable treatment option that works to reduce symptoms,” added Dom, a professor of psychiatry at the University of Antwerp in Belgium. “It is with delight that we see the results of this meta-analysis and we hope to see further research into this so we can move towards a solution to the unmet need within this community." Branco, however, emphasized that more research into CBD is needed before it can be considered as a treatment for autism. “There still needs to be considerable focus on further research with larger trials to clarify its efficacy and safety in managing ASD,” she said. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

▎药明康德内容团队报道根据公开信息，上周（3月24日~3月30日），全球范围内有至少9家致力于创新药研发的新锐公司宣布完成新一轮融资，其中1家来自中国。通过梳理，这些获得资本青睐的新锐公司正在开发的产品包括多肽、小分子、基因疗法等类型，针对的疾病领域涵盖纤维化疾病、免疫和炎症性疾病、癌症、神经退行性疾病、罕见眼部疾病、罕见遗传性神经肌肉疾病等。安达生物融资轮次：A轮融资金额：数千万元3月24日，安达生物宣布完成数千万元A轮融资。本轮融资由力鼎资本、浦耀信晔领投，临创司南、博通创投、德丰杰龙脉等机构跟投。根据安达生物新闻稿，本轮募集资金将重点用于推进核心管线——个性化肿瘤治疗性新抗原多肽疫苗PCNAT-01（胰腺癌个性化新抗原疫苗）的临床研究，同时加速其他在研项目的临床前开发。安达生物成立于2018年，是一家专注于个体化肿瘤新抗原疫苗研发的生物技术公司，在实体瘤治疗领域，该公司的核心产品PCNAT-01于2022年3月获得FDA孤儿药资格，于2024年和2025年分别在美国和中国获批IND。Augustine Therapeutics融资轮次：A轮融资金额：7770万欧元3月24日，Augustine Therapeutics公司宣布完成A轮融资，总额为7770万欧元（约8480万美元）。本轮融资由Novo Holdings与Jeito Capital联合领投，现有投资方Asabys Partners、礼来（Eli Lilly and Company）、AdBio Partners、V‑Bio Ventures、PMV、VIB、Gemma Frisius Fund、美国腓骨肌萎缩症（CMT）研究基金会及Newton Biocapital也参与了本轮融资。本轮获得资金将用于推动其主打在研疗法AGT-100216治疗CMT的临床开发，直至完成1/2期概念验证临床试验。AGT-100216是一款选择性抑制HDAC6的催化活性，同时保留其有益的非催化功能的新一代抑制剂。HDAC6参与神经退行性病变及组织衰老相关的细胞过程，其药理学抑制有潜力治疗多种疾病。除了针对CMT的研发项目，Augustine还开发了可穿越血脑屏障，以及具有外周限制性的另外两款HDAC6抑制剂，拓展了其管线在神经退行性疾病及心脏代谢疾病等多种适应症中的应用前景。Tempero Bio融资轮次：B轮融资金额：7000万美元3月24日，Tempero Bio公司宣布完成7000万美元B轮融资。本轮融资由8VC领投，Aditum Bio、Khosla Ventures及其他投资者参与。获得资金将用于推进在研疗法TMP‑301的临床研究。TMP‑301是一种下一代代谢型谷氨酸受体5（mGluR5）负向别构调节剂（NAM），旨在针对成瘾的神经生物学基础。该产品已经在酒精、可卡因和阿片类药物使用障碍的临床前模型中显示出潜力，目前已推进至2期临床研究阶段。NeuroNOS融资轮次：股权融资融资金额：200万美元3月24日，NeuroNOS宣布已经从私人投资者那里获得了200万美元的初始股权融资。NeuroNOS专注于开发自闭症谱系障碍（ASD）和其他复杂神经系统疾病（包括阿尔茨海默病和脑癌）的变革性治疗方法。本次投资将加速NeuroNOS公司在研的小分子药物的临床前开发，用于自闭症儿童患者的治疗。该药物源于NeuroNOS首席科学官Haitham Amal教授在希伯来大学（Hebrew University of Jerusalem）研究期间的创新发现，利用大脑中一氧化氮（NO）水平的调节来影响神经功能。研究表明，自闭症儿童的一氧化氮水平升高。在ASD小鼠模型和ASD儿童干细胞来源的神经元中，抑制神经元中NO的产生逆转了自闭症样表型。通过靶向和调节NO水平，NeuroNOS的药物旨在恢复正常的大脑信号，防止突触功能障碍，最终改善ASD儿童的行为和认知功能。Hillstar Bio融资轮次：A轮融资金额：6700万美元3月25日，Hillstar Bio宣布完成6700万美元的A轮融资，投资者包括Droia Ventures, Frazier Life Sciences, Novo Holdings, LifeArc Ventures, and Hummingbird Bioscience。Hillstar Bio专注于开发下一代自身免疫性疾病精确免疫疗法，其方法是选择性地靶向和消耗致病免疫细胞，同时保留健康的免疫细胞，为自身免疫性疾病患者提供持久缓解和免疫重置的潜力。本轮融资将用于推动Hillstar Bio的主要项目在2026年进入临床试验，该项目特异性靶向TRBV9+ T细胞，最初的重点是治疗中轴型脊柱关节炎（AxSpA）以及其他潜在免疫和炎症疾病。Hubble Therapeutics融资轮次：A轮融资金额：730万美元3月25日，Hubble Therapeutics宣布完成730万美元的A轮融资，用于推动其主要候选产品HUB-101进入人体临床试验。Hubble正在开发一种治疗儿童失明的基因疗法HUB-101，该产品自威斯康星校友研究基金会（WARF）许可引进，旨在治疗两种罕见眼部疾病：Leber先天性黑朦16型（LCA16）和雪花样玻璃体视网膜变性（SVD）。LCA16和SVD是由KCNJ13基因突变引起的严重的早发性视网膜营养不良，KCNJ13基因对视网膜色素上皮细胞中重要离子通道的功能至关重要。这些疾病通常在五岁前的儿童中表现出来，导致在接下来的二十年中进行性视网膜变性，最终导致失明。Character Biosciences融资轮次：B轮融资金额：9300万美元3月25日，Character Biosciences宣布完成超额认购的9300万美元B轮融资，以加速推进其针对退行性眼病的药物研发，首先针对年龄相关性黄斑变性（AMD）。此次融资由新投资者aMoon和Luma Group联合领投，同时获得博士伦（Bausch + Lomb）及Jefferson Life Sciences的参与，以及现有投资者Innovation Endeavors、Catalio Capital Management、S32与KdT Ventures的支持。Character公司两款主打药物分别针对视网膜细胞死亡和视力丧失的关键驱动因素。其中，CTX114为一款补体抑制剂，旨在减缓晚期干性AMD中地图样萎缩的进展；CTX203则是一款脂质调节剂，旨在预防AMD向晚期进展。Character预计这两个项目将在未来一年内进入临床试验。今年1月，Character Biosciences还宣布与博士伦达成合作，共同开发针对AMD的新型治疗药物。Tribune Therapeutics融资轮次：A轮融资金额：2300万欧元3月26日，Tribune Therapeutics宣布完成A轮2300万欧元融资，由新投资者LifeArc Ventures领投，种子投资者Novo Holdings、HealthCap、Innovestor's Life Science Fund和Inven2以及新的投资者Industrifonden和investor加入。不同于传统的纤维化疾病疗法多通过靶向炎症介质或生长因子来控制症状或减缓疾病进展，Tribune致力于开发针对纤维化根本原因的疾病修饰治疗方案，无论病因、组织或诊断如何。该公司成立于对CCN蛋白家族的突破性结构见解，该蛋白是疤痕形成的关键驱动因素，也是难以“完全靶向”的蛋白之一。主导项目TRX-44目前正在开发中，用于治疗纤维化疾病，包括特发性肺纤维化（IPF）。该产品通过模仿CCN5的结构和功能来防止疤痕（scar）的形成，具有对抗更广泛的纤维化疾病的潜力。Epicrispr Biotechnologies融资轮次：B轮融资金额：6800万美元3月26日，Epicrispr Biotechnologies宣布已获得6800万美元的B轮融资，由Ally Bridge Group领投，参与融资的还有公益创投机构SOLVE FSHD，以及其他新老投资者。所得款项将用于支持EPI-321的临床开发，这是一种表观遗传学基因调节疗法，拟开发用于遗传性神经肌肉疾病面肩肱型肌营养不良症（FSHD）。EPI-321旨在沉默DUX4的异常表达，DUX4是一种在FSHD中被错误激活并导致进行性肌肉变性的基因。EPI-321通过临床验证的AAV载体系统递送，在临床前模型中显示出对DUX4表达的强大抑制和对肌肉组织的保护作用。该产品的的首次人体临床试验计划于2025年进行。期待在资本的助力下，更多前沿疗法和技术能够更快惠及患者。参考资料：[1]各公司官网及公开资料本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。